Canexia Health's Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Developing the business case for bringing cancer testing in-house can be a daunting task for laboratory, pathology, and other scientific professionals. In this presentation, Dr. Gregory Tranah, of Sutter Health, discusses opportunities and challenges that bringing in-house testing to a large, complex, health system presents. Dr. Tranah will discuss critical success factors such as personalization, portability, safety, and accessibility for others who are considering embarking on this path.

COVID-19 has created serious challenges for people living with advanced-stage cancer. In response, Canexia Health launched Project ACTT this summer, a federally-funded program to provide liquid biopsy testing to 2,000 patients across Canada with advanced or metastatic breast, lung, and colorectal cancer. Here is one patient’s story.

COVID-19 has had dramatic impacts on all aspects of healthcare, including treatment selection and monitoring of late stage cancers. Last week, Brady Davis, Canexia's SVP of Corporate Development, moderated a workshop on this topic as part of the Association for Molecular Pathology 2020 conference, bringing together four global experts in oncology and pathology.

COVID-19 has had dramatic impacts on all aspects of healthcare, including treatment selection and monitoring of late stage cancers. This international, multidisciplinary panel discuss their experience and insights on maintaining high levels of care in the midst of a global pandemic, as well as their perspectives on how care may be transformed in the long-term.

We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.

Funding comes after the company meets key milestones with new collaborations and studies, product enhancements, and reimbursement progress.

DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.

British Columbia-based Digital Technology Supercluster has announced a cumulative investment of approximately $30 million into 17 projects, including Project ACTT led by Canexia Health, through its COVID-19 program, launched in April to contribute to Canada’s Plan to Mobilize Industry to fight the pandemic.